Lymphoma clinical trials
99 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
- A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
- First in Human, Dose Escalation Study of AN4005
- A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Post-Op Pain Control for Prophylactic Intramedullary Nailing.
- A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
- Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Studying TAK-243 in Patients With Advanced Cancer
- xDRIVE for Florida-based Cancer Patients
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
- HEARTS Trial for Thoracic Cancers
- Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
- Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
- DOAC - Dosing Options in AntiCoagulation Prophylaxis
- WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
- Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- Indocyanine Green (ICG) Guided Tumor Resection
- TCF-001 TRACK (Target Rare Cancer Knowledge) Study
- Communicating Health Options to Inform Care and Empower Strategic Care Planning (CHOICES): A Multi-layer Randomized Case Vignette Study.
- Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
- Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
- Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy
- Sample Collection and Tracking for the Developmental Therapeutics Clinic
- Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
- Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
- Study of CAR-T Therapy in Older Patients
- Collection of Tissue Samples for Cancer Research
- Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
- HPC Offered for PRESERVE Expansion
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Lymphoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.